ANTI-PD-L1 AND 4-1BB BIFUNCTIONAL ANTIBODY AND MEDICAL USE THEREOF

Title:

ANTI-PD-L1 AND 4-1BB BIFUNCTIONAL ANTIBODY AND MEDICAL USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2023/174140

Kind Code:

A1

Abstract:

Provided are an anti-PD-L1 and 4-1BB bifunctional antibody and medical use thereof. The selected 4-1BB antibody requires the support of a cross-linking effect in terms of immunoreactivity stimulation. Without the cross-linking effect, the 4-1BB antibody has no activity and thus does not produce toxic and side effects in the liver. In a tumor environment, tumor cells have relatively high levels of PD-L1 expression. The PD-L1/4-1BB bifunctional antibody binds by means of a PD-L1 antibody portion thereof to PD-L1 on the surface of a tumor cell, providing a relatively strong cross-linking effect for the 4-1BB antibody. Therefore, the immunostimulatory activity of the PD-L1/4-1BB bifunctional antibody can be significantly improved specifically in the tumor microenvironment, thereby avoiding or reducing the toxic and side effects produced by the 4-1BB antibody in the liver.

More Like This:

WO/2015/063339	PRODUCTION OF T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
JP2023511280	Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinating enzymes
JP2022543669	Novel antigen-binding molecule format

Inventors:

QIU JUNZHUAN (CN)
CHEN JUNYONG (CN)
WANG ZHENSHENG (CN)
SUN KAI (CN)
SUN JIAN (CN)
LI ZHONGLIANG (CN)
OU RISHAN (CN)

Application Number:

PCT/CN2023/080387

Publication Date:

September 21, 2023

Filing Date:

March 09, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

INNOLAKE BIOPHARMA HANGZHOU CO LTD (CN)

International Classes:

C07K16/46; A61K39/395; A61K47/68; A61P35/00; A61P35/02; C12N5/10; C12N15/13; C12N15/85

Foreign References:

CN114736303A	2022-07-12
CN113286825A	2021-08-20
CN110903391A	2020-03-24
CN112538116A	2021-03-23
CN110627906A	2019-12-31
CN112424228A	2021-02-26
CN113121698A	2021-07-16
CN112789292A	2021-05-11

Other References:

JEONG, S. ET AL.: "Novel Anti-4-1BB×PD- L1 Bispecific Antibody Augments Anti-Tumor Immunity Through Tumor-directed T-cell Activation and Checkpoint Blockade", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, 6 July 2021 (2021-07-06), XP093006433, DOI: 10.1136/jitc-2021-002428

Attorney, Agent or Firm:

ZHONGLUN LAW FIRM (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: WORK DISPLAY METHOD AND APPARATUS, ELECTRONIC DEVICE, STORAGE MEDIUM, AND PROGRAM PRODUCT

Next Patent: COMMUNICATION METHOD AND APPARATUS